310 related articles for article (PubMed ID: 35231177)
21. Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects.
Huang T; Peng L; Han Y; Wang D; He X; Wang J; Ou C
Front Immunol; 2022; 13():922301. PubMed ID: 36090974
[TBL] [Abstract][Full Text] [Related]
22. Current Status and Future Perspectives on MRNA Drug Manufacturing.
Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
[TBL] [Abstract][Full Text] [Related]
23. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
Maruggi G; Zhang C; Li J; Ulmer JB; Yu D
Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823
[TBL] [Abstract][Full Text] [Related]
24. Formulation and Delivery Technologies for mRNA Vaccines.
Zeng C; Zhang C; Walker PG; Dong Y
Curr Top Microbiol Immunol; 2022; 440():71-110. PubMed ID: 32483657
[TBL] [Abstract][Full Text] [Related]
25. A Comprehensive Review of mRNA Vaccines.
Gote V; Bolla PK; Kommineni N; Butreddy A; Nukala PK; Palakurthi SS; Khan W
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36769023
[TBL] [Abstract][Full Text] [Related]
26. Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects.
Edwards DK; Carfi A
Curr Opin Immunol; 2022 Aug; 77():102214. PubMed ID: 35671599
[TBL] [Abstract][Full Text] [Related]
27. The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology.
Ye Z; Harmon J; Ni W; Li Y; Wich D; Xu Q
ACS Nano; 2023 Aug; 17(16):15231-15253. PubMed ID: 37535899
[TBL] [Abstract][Full Text] [Related]
28. mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.
Matarazzo L; Bettencourt PJG
Front Immunol; 2023; 14():1172691. PubMed ID: 37168860
[TBL] [Abstract][Full Text] [Related]
29. Current state of, prospects for, and obstacles to mRNA vaccine development.
Aljabali AAA; Bashatwah RM; Obeid MA; Mishra V; Mishra Y; Serrano-Aroca Á; Lundstrom K; Tambuwala MM
Drug Discov Today; 2023 Feb; 28(2):103458. PubMed ID: 36427779
[TBL] [Abstract][Full Text] [Related]
30. mRNA vaccine in cancer therapy: Current advance and future outlook.
Li Y; Wang M; Peng X; Yang Y; Chen Q; Liu J; She Q; Tan J; Lou C; Liao Z; Li X
Clin Transl Med; 2023 Aug; 13(8):e1384. PubMed ID: 37612832
[TBL] [Abstract][Full Text] [Related]
31. Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines.
Lee J; Woodruff MC; Kim EH; Nam JH
Exp Mol Med; 2023 Jul; 55(7):1305-1313. PubMed ID: 37430088
[TBL] [Abstract][Full Text] [Related]
32. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.
Deng Z; Tian Y; Song J; An G; Yang P
Front Immunol; 2022; 13():887125. PubMed ID: 35720301
[TBL] [Abstract][Full Text] [Related]
33. mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.
Chen P; Shi X; He W; Zhong G; Tang Y; Wang H; Zhang P
Hum Vaccin Immunother; 2022 Dec; 18(1):2040330. PubMed ID: 35321627
[TBL] [Abstract][Full Text] [Related]
34. [New Hopes in Vaccine Technology: mRNA Vaccines].
Yılmaz E
Mikrobiyol Bul; 2021 Apr; 55(2):265-284. PubMed ID: 33882657
[TBL] [Abstract][Full Text] [Related]
35. A review of technological developments in lipid nanoparticle application for mRNA vaccination.
Yeh TF; Lin C; Sung HC
Hum Vaccin Immunother; 2023 Aug; 19(2):2256040. PubMed ID: 37705354
[TBL] [Abstract][Full Text] [Related]
36. WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20-22 April 2021.
Liu MA; Zhou T; Sheets RL; Meyer H; Knezevic I
Emerg Microbes Infect; 2022 Dec; 11(1):384-391. PubMed ID: 35001848
[TBL] [Abstract][Full Text] [Related]
37. Design Strategies for and Stability of mRNA-Lipid Nanoparticle COVID-19 Vaccines.
Liu T; Tian Y; Zheng A; Cui C
Polymers (Basel); 2022 Oct; 14(19):. PubMed ID: 36236141
[TBL] [Abstract][Full Text] [Related]
38. Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases.
Gu Y; Yang J; He C; Zhao T; Lu R; Liu J; Mo X; Wen F; Shi H
Signal Transduct Target Ther; 2023 Jul; 8(1):273. PubMed ID: 37455272
[TBL] [Abstract][Full Text] [Related]
39. Developing mRNA for Therapy.
Karikó K
Keio J Med; 2022; 71(1):31. PubMed ID: 35342149
[TBL] [Abstract][Full Text] [Related]
40. mRNA vaccines: the most recent clinical applications of synthetic mRNA.
Kwon S; Kwon M; Im S; Lee K; Lee H
Arch Pharm Res; 2022 Apr; 45(4):245-262. PubMed ID: 35426547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
